DW 166HC
Alternative Names: 166 holmium chitosan complex; 166 holmium poliglusam; Holmium 166 chitosan; MilicanLatest Information Update: 10 Feb 2016
At a glance
- Originator Dong Wha
- Developer Dong Wha Pharmaceutical
- Class Antineoplastics; Organometallic compounds; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Liver cancer
- Discontinued Brain cancer; Rheumatoid arthritis
Most Recent Events
- 10 Feb 2016 DW 166HC is available for licensing as of 10 Feb 2016. www.dong-wha.co.kr
- 02 Nov 2007 Clinical trials in Brain cancer in South Korea (Intratumoural)
- 02 Nov 2007 Discontinued - Phase-II for Rheumatoid arthritis in South Korea (unspecified route)